GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (OTCPK:SYRS) » Definitions » PB Ratio

SYRS (Syros Pharmaceuticals) PB Ratio : (As of Apr. 05, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-05), Syros Pharmaceuticals's share price is $0.0238. Syros Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2024 was $-0.42. Hence, Syros Pharmaceuticals's PB Ratio of today is .

The historical rank and industry rank for Syros Pharmaceuticals's PB Ratio or its related term are showing as below:

During the past 10 years, Syros Pharmaceuticals's highest PB Ratio was 13.04. The lowest was 0.43. And the median was 3.57.

SYRS's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.22
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Syros Pharmaceuticals's average Book Value Per Share Growth Rate was -123.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -66.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -45.70% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Syros Pharmaceuticals was -13.30% per year. The lowest was -66.10% per year. And the median was -19.10% per year.

Back to Basics: PB Ratio


Syros Pharmaceuticals PB Ratio Historical Data

The historical data trend for Syros Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals PB Ratio Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.78 6.74 2.37 0.57 12.37

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.25 12.37 9.50 - -

Competitive Comparison of Syros Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Syros Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syros Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's PB Ratio falls into.


;
;

Syros Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Syros Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=0.0238/-0.415
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Syros Pharmaceuticals  (OTCPK:SYRS) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Syros Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Syros Pharmaceuticals Business Description

Traded in Other Exchanges
Address
35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Executives
Nancy A Simonian director, 10 percent owner, officer: President & CEO C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Gerald E Quirk officer: Chief Legal Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David Roth officer: Chief Medical Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jason Haas officer: Chief Financial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Kristin Stephens officer: Chief Development Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley officer: Chief Commercial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
Eric R Olson officer: Chief Scientific Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson director ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh director C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Richard A Young director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn officer: Chief Business Officer C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421